One patent currently held, every record listed here
2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1 more record may belong here and awaits a decision; it is not counted.
The next term ends in Jun 2033. from the record
Of the 2 now held by other companies, 2 name Cypralis Limited as their current owner. Each row says so.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Jun 2033
Next term end
1
Patent families
When these terms end
Each bar runs from grant to computed term end. 2015 to 2033.20192023202720312033
A dotted end marks a recorded terminal disclaimer this site has not resolved: the term can only be shorter than the bar, never longer.
Every computed term in this portfolio is shown above.Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 1 of the currently held patents qualifies as notable.
Formerly held, still cited
Notable
Ends Jun 2033 · Medium confidence
Granted 2017 and renewed at every maintenance window due so far. Protection runs to 2033.
now held by Cypralis Limited
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due May 12, 2027The maintenance fee for Macrocyclic Inhibitors of Flaviviridae Viruses (US 10,472,392) comes due May 12, 2027. Unpaid by Nov 12, 2027, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Macrocyclic Inhibitors of Flaviviridae Viruses | 1 in force | to Jun 2033 |
Patents held now
Soonest term end first.
Showing 1 to 1 of 1
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,472,392 | Macrocyclic Inhibitors of Flaviviridae Viruses held by Cypralis Limited In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 1: 2 patents in force now held by others · 7 patents ended · 2 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
5 terminal disclaimers are on file with no resolved reference. No cap is applied and none is guessed
1 computed term date comes from a chain with an unresolved parent. A continuity parent has not yet been fetched from USPTO's records. The term is dated from this application's own claim; no earlier date is assumed until the parent is resolved.